Cover Image
市場調查報告書

躁鬱症:流行病學、病患人數的市場預測,治療流程,已上市/開發平台藥物分析

Bipolar disorder: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis

出版商 Datamonitor Healthcare 商品編碼 365212
出版日期 內容資訊 英文 319 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
躁鬱症:流行病學、病患人數的市場預測,治療流程,已上市/開發平台藥物分析 Bipolar disorder: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis
出版日期: 2016年06月01日 內容資訊: 英文 319 Pages
簡介

躁鬱症的治療藥的市場上,現在學名藥壓倒了市場大半,那妨礙市場成長。可破除這個情形的開發中產品還沒出現。

本報告提供躁鬱症的已上市/臨床實驗中 (開發平台上)的治療藥相關分析,各產品的市場規模的估計值,左右今後的市場趨勢的諸要素,及最高成長率領域,與其他的精神疾病 (的治療藥) 的差異,標準的治療方法,主要的未滿足需求等相關調查。

市場預測:躁鬱症

  • 摘要整理
  • 市場概要與趨勢
  • 市場定義和分析方法
  • Abilify (Aripiprazole)
  • Abilify Maintena (Aripiprazole)
  • Latuda (Lurasidone)
  • Risperdal Consta (risperidone)
  • Saphris (asenapin)
  • Seroquel/Seroquel XR (quetiapine fumarate)
  • Vraylar (cariprazine)
  • 一次調查技術

治療方法:躁鬱症

  • 摘要整理
  • 一次調查技術
  • 疾病定義與診斷方法
  • 患者的分類
  • 各國治療系統
  • 目前治療選擇
  • 處方的趨勢
  • 躁鬱症相關的未滿足需求

流行病學:美國、日本、歐洲的躁鬱症

  • 摘要整理
  • 疾病定義
  • 全球各地的趨勢的差異
  • 風險要素
  • 併發症
  • 資訊來源、分析方法
  • 市場預測
  • 預測:雙極性I型障礙
  • 預測:雙極性II型障礙
  • 流行病學者的見解
  • 分析的優勢與限制
  • 附錄

已上市藥物:躁鬱症

  • 摘要整理
  • 產品概要
  • 其他的已上市藥物
  • 產品簡介:Abilify
  • 產品簡介:Geodon
  • 產品簡介:Lamictal
  • 產品簡介:Latuda
  • 產品簡介:Risperdal/Risperdal Consta
  • 產品簡介:Saphris
  • 產品簡介:Seroquel/Seroquel XR
  • 產品簡介:Vraylar
  • 產品簡介:Zyprexa

開發中產品:氣喘

  • 摘要整理
  • 臨床實驗開發平台概要
  • 分析目標產品簡介
  • 臨床實驗的設計
  • 未來的治療方法
  • 最近臨床實驗中止的藥物
  • 產品簡介 (最後階段):ITI-007

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC13101

Generic dominance will prevent the growth of the bipolar disorder market, and few pipeline candidates show promise to completely reverse this trend.

This report addresses the following questions:

  • What are the key events shaping the bipolar disorder market dynamics over 2014-23?
  • Which segments of the market provide opportunities for growth?
  • How does the bipolar disorder pipeline compare to other psychiatric indications, and what are the candidates to look out for?
  • How do currently available bipolar disorder drugs compare to one another?
  • What is the standard of care in bipolar disorder, and which are the key unmet needs in treatment?

TABLE OF CONTENTS

FORECAST: BIPOLAR DISORDER

  • 1. Executive Summary
  • 2. Market Overview and Trends
  • 3. Market Definition and Methodology
  • 4. Abilify (aripiprazole)
  • 5. Abilify Maintena (aripiprazole)
  • 6. Latuda (lurasidone)
  • 7. Risperdal Consta (risperidone)
  • 8. Saphris (asenapine)
  • 9. Seroquel/Seroquel XR (quetiapine fumarate)
  • 10. Vraylar (cariprazine)
  • 11. Primary Research Methodology

TREATMENT: BIPOLAR DISORDER

  • 12. Executive Summary
  • 13. Primary Research Methodology
  • 14. Disease Definition and Diagnosis
  • 15. Patient Segmentation
  • 16. Country Treatment Trees
  • 17. Current Treatment Options
  • 18. Prescribing Trends
  • 19. Unmet Needs in Bipolar Disorder

EPIDEMIOLOGY: BIPOLAR DISORDER IN THE US, JAPAN, AND 5EU

  • 20. Executive Summary
  • 21. Disease Definition
  • 22. Global Variation
  • 23. Risk Factors
  • 24. Co-Morbidities
  • 25. Sources and Methodology
  • 26. Forecast
  • 27. Forecast: Bipolar Disorder I
  • 28. Forecast: Bipolar Disorder II
  • 29. Epidemiologist Insight
  • 30. Strengths and Limitations
  • 31. Bibliography

MARKETED DRUGS: BIPOLAR DISORDER

  • 32. Executive Summary
  • 33. Product Overview
  • 34. Other Marketed Drugs
  • 35. Product profile: Abilify
  • 36. Product profile: Geodon
  • 37. Product profile: Lamictal
  • 38. Product profile: Latuda
  • 39. Product profile: Risperdal/Risperdal Consta
  • 40. Product profile: Saphris
  • 41. Product profile: Seroquel/Seroquel XR
  • 42. Product profile: Vraylar
  • 43. Product profile: Zyprexa

PIPELINE: BIPOLAR DISORDER

  • 44. Executive Summary
  • 45. Clinical Pipeline Overview
  • 46. Target Product Profile
  • 47. Clinical Trial Design
  • 48. The Future of Treatment
  • 49. Recently Discontinued Drugs
  • 50. Product profile (late stage): ITI-007
Back to Top